AS2677131 is a potent and orally active PIKfyve inhibitor. It suppresses IL-12p40, IL-6, and IL-1β through the PIKfyve-c-Rel pathway and selectively inhibits the DNA-binding activity of c-Rel with IL-12p40 and IL-1β promoters. Additionally, AS2677131 represses the expression of MHCII molecules on B cells. This compound is applicable for research in inflammation and immunology, such as in arthritis.

AS2677131 suppresses the production of IL-12p40 with an IC50 value of 2.4 nM and reduces the levels of IL-1β and IL-6 in RAW264.7 mouse macrophages. At concentrations ranging from 0.1 to 10000 nM, AS2677131 inhibits IL-12p40 and IL-6 in mouse peritoneal macrophages， and similarly affects mouse bone marrow-derived dendritic cells. The compound shows no significant effect on intracellular Ca2+ influx in Ramos cells at 10 μM. It inhibits PI (3,5) P2 generation in RAW264.7 cells by over 90% at a concentration of 200 nM， and at 100 nM for 2 hours, it increases the volume of RAW264.7 cells and induces the formation of numerous cytoplasmic vesicles. Additionally, at concentrations between 10 and 100 nM for 2 hours, AS2677131 reduces promoter activity and inhibits c-Rel binding to IL-12p40 and IL-1β promoters in RAW264.7 cells. Furthermore, at 100 nM for 2 hours, it decreases the level of p-Akt in RAW264.7 cells.

AS2677131, administered orally in doses ranging from 1 to 30 mg/kg, has been shown to reduce the levels of IL-12p40, IL-6, and TNFα in plasma from rats treated with Poly (I:C) and MDP. At doses of 1 to 10 mg/kg, this compound decreases the expression of MHC class II molecules on CD45R+ B cells in rats. Furthermore, when given at 1 to 10 mg/kg orally once daily for 24 consecutive days, AS2677131 alleviates inflammation in rats with adjuvant-induced arthritis.